Skip to main content
OpenTrials
Completed

NCT Number: NCT07112755

Prediction Model for Osteopenia in Patients With Psoriasis

This study aims to develop a clinical prediction model for osteopenia in patients with psoriasis. By retrospectively analyzing demographic, laboratory, and lifestyle variables, the investigators will identify risk factors associated with decreased bone mineral density (BMD) in this population. The study will facilitate the identification of high-risk individuals and provide evidence for early screening and intervention strategies.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Chinese PLA General Hosptial

Beijing, Beijing Municipality, 100853, China

About this study

Psoriasis is a chronic inflammatory skin disease associated with various systemic comorbidities, including an increased risk of bone loss. Recent studies suggest that patients with psoriasis have a significantly higher incidence of osteopenia and osteoporosis than the general population, potentially due to systemic inflammation and shared risk factors. All enrolled patients will undergo dual-energy X-ray absorptiometry (DEXA) scans to assess bone mineral density (BMD). Based on the results, patients will be categorized into normal BMD and osteopenia groups. Demographic data (age, sex, height, weight, BMI), clinical variables (disease duration, CRP, ESR, blood glucose, blood lipids, blood pressure), and lifestyle factors (smoking, alcohol use) will be collected and analyzed. Univariate and multivariate logistic regression analyses will be performed to identify independent risk factors. A prediction model will be constructed and evaluated using ROC curve analysis to assess sensitivity, specificity, and accuracy. The objective of this study is to develop a validated tool to assist clinicians in identifying patients with psoriasis at high risk for osteopenia, thereby enabling early screening and preventive management to reduce future fracture risk.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Diagnosis of plaque psoriasis according to established diagnostic criteria
  • Age ≥ 18 years
  • Willingness to participate in the study and provide written informed consent

Exclusion criteria

  • Severe hepatic or renal dysfunction
  • Coexisting immune, endocrine, or malignant diseases that may affect bone metabolism
  • Congenital joint deformities, history of joint trauma, or joint replacement surgery
  • Use of systemic corticosteroids, calcium supplements, or bisphosphonates within the past 3 months
  • Psychiatric or psychological disorders

Treatment and study plan

Primary outcomes

  1. Occurrence of Osteopenia in Patients With Psoriasis

    Time frame: At the time of DEXA assessment during enrollment

    Bone mineral density (BMD) will be assessed using dual-energy X-ray absorptiometry (DEXA) at the lumbar spine and/or femoral neck. Osteopenia is defined as a T-score between -1.0 and -2.5 according to WHO criteria. Patients will be categorized accordingly.

Sponsors and collaborators

Lead sponsor

Chongli Yu

Other

Registry information

Official study title

Development of a Risk Prediction Model for Osteopenia in Patients With Psoriasis: A Cross-Sectional Study

Important dates

Study start
2022
Primary completion
2022
Study completion
2022
First posted
Aug 8, 2025
Registry last updated
Aug 13, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.